Related Articles
Concurrent use of nivolumab and radiotherapy for patients with metastatic non‑small cell lung cancer and renal cell carcinoma with oligometastatic disease progression on nivolumab
Prognostic outcome in patients treated with tyrosine kinase inhibitors as first-line molecular-targeted therapy for metastatic renal cell carcinoma: Experience in real-world clinical practice in Japan
A comparative study of nivolumab and axitinib in terms of overall survival, treatment continuation, and cost for patients with metastatic renal cell carcinoma
Progression‑free survival of first‑line treatment with molecular‑targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma
Oncological outcomes classified according to metastatic lesions in the era of molecular targeted drugs for metastatic renal cancer